Royalty Pharma vs Sarepta Therapeutics
RPRX and SRPT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RPRX and SRPT compare
Royalty Pharma is the larger company, worth 20 times as much as Sarepta Therapeutics ($38.6B against $2.0B).
Royalty Pharma grew revenue faster over the last twelve months (10.0% versus −20.4% for Sarepta Therapeutics).
Royalty Pharma keeps more of each dollar of sales as profit, with a net margin of 32.1% compared with −6.9% at Sarepta Therapeutics.
Royalty Pharma pays a dividend yielding 1.4%; Sarepta Therapeutics does not pay one.
Sarepta Therapeutics scores higher on the StockData Score (12 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RPRX | SRPT |
|---|---|---|
| Size and price | ||
| Market cap | $38.6B | $2.0B |
| Share price | $67.18 | $18.62 |
| Change, 1 year | 83.2% | −20.6% |
| Change, 5 years | 70.0% | −79.1% |
| Beta (5Y) | 0.41 | 1.02 |
| Employees | 100 | 835 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 2 (better) | 0 |
| Valuation | ||
| P/E | 38.2× | – |
| P/S | 15.2× | 1.0× (better) |
| P/B | – | 1.3× |
| EV/EBITDA | 32.9× | – |
| P/FCF | – | 24.0× |
| PEG | 0.24 | – |
| FCF yield | – | 4.2% |
| Fair value | $45.40 | $109.03 |
| Margin of safety | −48.0% | 82.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.0% (better) | −20.4% |
| Revenue growth, 5Y average | 2.3% | 32.4% (better) |
| Net income growth (TTM) | −20.4% | – |
| EPS growth (TTM) | −19.3% | – |
| EPS growth, 5Y average | 6.2% | – |
| Profitability | ||
| Operating margin | 59.6% (better) | −7.3% |
| Net margin | 32.1% (better) | −6.9% |
| FCF margin | – | 4.1% |
| Return on equity | – | −9.3% |
| Return on invested capital | – | −16.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | 5.37 | – |
| Interest coverage | 4.2× | – |
| Current ratio | 2.80 | 4.42 (better) |
| Altman Z-score | 2.93 (better) | −0.17 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | – |
| Buyback yield | 0.83% | – |
| Shareholder yield | 2.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 63.8% | 102% |
| Held by insiders | 22.6% | 5.9% |
| Insider net buying, 12 months | −$92.6M | −$417K (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 2.9% | 22.9% |
Go deeper
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
- SRPT stock overview
- SRPT income statement
- SRPT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.